ATE550437T1 - Verfahren zur expression und reinigung von immunotoxinen - Google Patents

Verfahren zur expression und reinigung von immunotoxinen

Info

Publication number
ATE550437T1
ATE550437T1 AT04779747T AT04779747T ATE550437T1 AT E550437 T1 ATE550437 T1 AT E550437T1 AT 04779747 T AT04779747 T AT 04779747T AT 04779747 T AT04779747 T AT 04779747T AT E550437 T1 ATE550437 T1 AT E550437T1
Authority
AT
Austria
Prior art keywords
expressing
immunotoxins
purifying
pichia pastoris
immunotoxin
Prior art date
Application number
AT04779747T
Other languages
English (en)
Inventor
David Neville
Jung-Hee Woo
Yuan-Yi Liu
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE550437T1 publication Critical patent/ATE550437T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT04779747T 2003-08-01 2004-08-02 Verfahren zur expression und reinigung von immunotoxinen ATE550437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49192303P 2003-08-01 2003-08-01
PCT/US2004/024786 WO2005012495A2 (en) 2003-08-01 2004-08-02 Methods for expression and purification of immunotoxins

Publications (1)

Publication Number Publication Date
ATE550437T1 true ATE550437T1 (de) 2012-04-15

Family

ID=34115570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779747T ATE550437T1 (de) 2003-08-01 2004-08-02 Verfahren zur expression und reinigung von immunotoxinen

Country Status (7)

Country Link
US (2) US7892786B2 (de)
EP (2) EP2314711A1 (de)
CN (3) CN1863921B (de)
AT (1) ATE550437T1 (de)
AU (1) AU2004262023B2 (de)
CA (1) CA2534360C (de)
WO (1) WO2005012495A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017823A2 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
US7968300B2 (en) 2007-11-21 2011-06-28 Li-Te Chin Method of isolating regulatory T cells from human samples
AU2009215341B2 (en) * 2008-02-20 2015-03-26 Glaxosmithkline Biologicals S.A. Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
WO2010089385A1 (en) * 2009-02-06 2010-08-12 Novozymes Biopharma Dk A/S Purification process
EP2280063A1 (de) * 2009-07-28 2011-02-02 Consiglio Nazionale delle Ricerche Pichia pastoris als Wirt zur Herstellung von dem ribosomdeaktivierendem Protein (RIP) Saporin und Fusion von Saporin mit Chimaeras
JP6553515B2 (ja) * 2012-12-20 2019-07-31 メディミューン，エルエルシー 免疫複合体の製造方法
WO2014125429A1 (en) * 2013-02-13 2014-08-21 Centre For Cellular And Molecular Platforms Culture medium for growth of recombinant proteins
CN105579053B (zh) * 2013-08-06 2021-08-31 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
KR20160131226A (ko) * 2015-05-06 2016-11-16 숭실대학교산학협력단 다양한 범위의 소수성을 갖는 하이드로콜로이드의 제조방법
CN108690138A (zh) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
WO2020172344A1 (en) 2019-02-19 2020-08-27 The Regents Of The University Of Colorado, A Body Corporate Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells
EP4106812A4 (de) * 2020-02-18 2024-02-21 The Regents of the University of Colorado, a Body Corporate Zusammensetzungen und verfahren zur induzierung von immuntoleranz bei transplantationsempfängern
CN111534444B (zh) * 2020-03-19 2023-11-14 山西大禹生物工程股份有限公司 高密度培养毕赤酵母流加盐的方法
WO2025091264A1 (zh) * 2023-10-31 2025-05-08 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物用于制备治疗gvhd的药物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288254B2 (en) * 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
JP3794748B2 (ja) * 1996-03-04 2006-07-12 第一アスビオファーマ株式会社 メタノール代謝系を有する微生物の培養法
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US6723536B2 (en) * 1999-12-03 2004-04-20 Entremed, Inc. Method of producing and purifying angiostatin
CA2409746C (en) 2000-05-18 2014-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CN1289678C (zh) * 2002-06-13 2006-12-13 长春奇龙生物技术研究所 高表达、高纯度、高活性基因重组人溶菌酶的生产及用途

Also Published As

Publication number Publication date
CA2534360A1 (en) 2005-02-10
US7892786B2 (en) 2011-02-22
CN102533910A (zh) 2012-07-04
EP1664321A2 (de) 2006-06-07
WO2005012495A2 (en) 2005-02-10
CN102533910B (zh) 2014-12-10
EP2314711A1 (de) 2011-04-27
US20060216782A1 (en) 2006-09-28
US20130217861A1 (en) 2013-08-22
CN104356241A (zh) 2015-02-18
AU2004262023B2 (en) 2011-03-10
CA2534360C (en) 2014-01-28
EP1664321B1 (de) 2012-03-21
EP1664321A4 (de) 2007-02-07
CN1863921B (zh) 2011-11-16
WO2005012495A3 (en) 2005-03-31
US8921097B2 (en) 2014-12-30
CN1863921A (zh) 2006-11-15
AU2004262023A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE218036T1 (de) Verfahren zur herstellung eines proteinhydrolysates
EP1664321A4 (de) Verfahren zur expression und reinigung von immunotoxinen
DE60325188D1 (de) Verfahren zur herstellung von sterilen, stabilisierten nanodispersionen
ATE474847T1 (de) Verfahren zur herstellung von dipeptiden
PL374782A1 (en) Animal protein free media for cultivation of cells
DE60238745D1 (de) Glucosamin und verfahren zur herstellung von glucosamin aus mikrobieller biomasse
DE69928845D1 (de) Methode zur Herstellung von L-Serin mittels Fermentation
EP1576108A4 (de) Nitrilasen, diese codierende nukleinsäuren sowie verfahren zur herstellung und verwendung davon
DE60216756D1 (de) Verfahren zur herstellung von hochdichten produkten aus rostfreiem stahl
AT4947U3 (de) Vollnarbiges rindnappaleder und verfahren zur herstellung desselben
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
DE69929264D1 (de) Methode zur Herstellung von L-Serin mittels Fermentation
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
DE60333304D1 (de) Gleitteil und verfahren zur herstellung des gleitteils
ATE451018T1 (de) Verfahren zur herstellung von sauermilchprodukten mit enzymen bakteriellen ursprungs
ATE360065T1 (de) Verfahren zur herstellung von matrizen-dna und verfahren zur proteinherstellung in einem zellfreien proteinsynthesesystem unter verwendung davon
DE59907055D1 (de) Verfahren zur herstellung von tetrachlorkohlenstoffarmen phosgen
DE60143034D1 (de) Optisch reines (-) clethodim, sowie dieses enthaltende zusammensetzungen und verfahren zur kontrolle von pflanzenwachstum
DE60006552D1 (de) Verfahren zur herstellung von exopolysaccharide
ATE538209T1 (de) L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin
DE50103394D1 (de) Verfahren zur enzymatischen racematspaltung von aminomethyl-aryl-cyclohexanol-derivaten
ATE553194T1 (de) Verfahren zur dipeptidherstellung
DE602005020838D1 (de) Pflanzen mit verbesserten wachstumseigenschaften und verfahren zur herstellung davon
ATE386027T1 (de) Verfahren zur herstellung von valsartan